市场调查报告书
商品编码
1533609
生物标记市场规模、份额、成长分析,按产品/服务、按类型、按技术、按应用、按地区 - 产业预测,2024-2031Biomarkers Market Size, Share, Growth Analysis, By Product & Service, By Type, By Technology, By Application, By Region - Industry Forecast 2024-2031 |
2022年全球生物标记市场规模将为669.7亿美元,高于2023年的758.8亿美元,在预测期(2024-2031)至2031年期间复合年增长率为13.3%,预计将达到2060.4亿美元。
该市场受到多种因素的推动,包括由于癌症发病率上升而导致伴同性诊断的重要性日益增加、生物标誌物研究资金的增加以及从正在进行的研究中获得的重要见解。例如,2023年10月,波士顿大学研究人员获得了美国国立卫生研究院460万美元的津贴,用于开发肺癌的新生物标记。研究在发现多种疾病的有效治疗方法方面发挥重要作用,包括癌症、心血管疾病、免疫失调和神经系统疾病。它也有助于早期发现和阐明这些疾病的预防方法。随着公共和私人资金的增加,该领域的投资巨大。例如,2022 年 3 月,Quanterix Corp. 宣布阿兹海默症药物发现基金会提供资金,以加速阿兹海默症诊断血浆检验的开发。预计未来几年生物标记在感染疾病诊断中的作用也将显着扩大。根据《微生物学前沿》报导,已经确定了多种疾病的潜在基于 MicroRNA 的生物标记物,包括鼻病毒、流感、结核病、爱滋病毒、疟疾、伊波拉出血热和亨德拉病毒。这些基于微型RNA的生物标记旨在促进感染的早期检测。此外,生物标记也用于神经系统疾病的治疗,以测量分子并监测大脑的状态。
Global Biomarkers Market size was valued at USD 66.97 Billion in 2022 and is expected to rise from USD 75.88 Billion in 2023 to reach a value of USD 206.04 Billion by 2031, at a CAGR of 13.3% over the forecast period (2024-2031).
The market is expected to experience growth due to several factors, including the increasing significance of companion diagnostics driven by rising cancer rates, increased funding for biomarker research, and significant findings from ongoing studies. For example, in October 2023, researchers from Boston University received a $4.6 million grant from the National Institutes of Health to develop new biomarkers for lung cancer. Research plays a crucial role in discovering effective treatments for a variety of conditions such as cancer, cardiovascular, immunological, and neurological diseases. It also helps in understanding early detection and preventive measures for these diseases. Investment in this field has been notable, with increased public and private funding. For instance, in March 2022, Quanterix Corp. announced that the Alzheimer's Drug Discovery Foundation had provided funding to accelerate the development of a diagnostic plasma test for Alzheimer's disease. The role of biomarkers in diagnosing infectious diseases is also expected to expand significantly in the coming years. According to *Frontiers in Microbiology*, potential MicroRNA-based biomarkers have been identified for various illnesses, including rhinoviruses, influenza, tuberculosis, HIV, malaria, Ebola, and Hendra virus. These MicroRNA-based biomarkers are designed to facilitate the early detection of infections. Additionally, biomarkers are utilized in managing neurological diseases to measure molecules and monitor brain conditions.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Biomarkers Market Segmental Analysis
The biomarkers market is segmented based on Product & Service, Type, Research Area, Technology, Disease Indication, Application, End User, and Region. Based on Product & Service, the market is segmented into Consumables (Assay Kits, Reagents & Chemicals, Columns & Filters), Services, and Software. Based on Type, the market is segmented into Safety Biomarkers, Efficacy Biomarkers (Predictive Biomarkers, Surrogate Biomarkers, Pharmacodynamic Biomarkers, Prognostic Biomarkers), Validation Biomarkers. Based on Research Area, the market is segmented into Genomics, Proteomics, Metabolomics, and Other Research Areas. Based on Technology, the market is segmented into Immunoassays (ELISA, Protein Microarrays, Western Blot), NGS, PCR, Mass Spectrometry, Chromatography, and Other Technologies. Based on Disease Indication, the market is segmented into Cancer, Infectious Diseases, Immunological Disorders, Neurological Disorders, Cardiovascular Disorders, and Other Disease Indications. Based on Application, the market is segmented into Clinical Diagnostics, Drug Discovery & Development, Personalized Medicine, Clinical Research, and Other Applications. Based on End User, the market is segmented into Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Laboratories, Academic & Research Institutes, and Other End Users. Based on Region, the biomarkers market is segmented into North America, Europe, Asia-Pacific, South America, and Middle East and Africa.
Drivers of the Global Biomarkers Market
The increasing prevalence of chronic diseases has heightened the need for advanced early detection equipment. Biomarkers play a vital role by enabling the identification and monitoring of diseases at a molecular level. Advances in omics platforms, including genomics and proteomics, are driving the development of new biomarkers, thereby improving diagnostic capabilities. Furthermore, the growing emphasis on personalized medicine and precise therapeutic strategies is boosting the demand for biomarkers that can tailor treatments to individual patient profiles.
Restraints in the Global Biomarkers Market
Several challenges have made biomarker validation and standardization difficult. Variability in biomarker effects and issues preventing their integration into clinical practice are key obstacles. The slow implementation of biomarkers is partly due to policy concerns and the need for more rigorous validation methods. Additionally, there are ethical and regulatory issues related to the privacy and safety of patient information in biomarker-based diagnostics. High development costs, particularly in the discovery of new biomarkers, further restrict their widespread use.
Market Trends of the Global Biomarkers Market
Liquid biopsy is an innovative, minimally invasive diagnostic technique that detects biomarkers in a patient's blood or other fluids. Gaining increasing attention in the biomarkers market, liquid biopsy facilitates early cancer detection and disease diagnosis, and can also assess treatment effectiveness. Several companies are actively working on commercializing liquid biopsy tests, and this market is expected to grow rapidly in the coming years.